rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cognition Therapeutics, Inc.

CGTX · Nasdaq

Health CareBiotechnologyNot moving yet

CGTX stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 31.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 39
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$65K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
66 (-7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$63KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Anthony CaggianoChief Medical Officerbought10,000at $1.1116 Apr 2026filed 20 Apr 2026
Lisa RicciardiCEO & Presidentbought9,175at $1.1016 Apr 2026filed 20 Apr 2026
John Brendan DoyleChief Financial Officerbought10,000at $1.1316 Apr 2026filed 20 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders66-7 on the quarter
New · exited5 · 12
Reported value$26.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BIOS Capital Management, LPunchanged · filed 14 Aug 20266,000,000$6.9M00.0%
DAVENPORT & Co LLCadded · filed 13 Jul 20264,259,511$4.9M+1,366,703+47.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,438,775$4.0M+436,988+14.6%
BlackRock, Inc.added · filed 7 Aug 20261,261,993$1.5M+293,631+30.3%
Chescapmanager LLCunchanged · filed 14 Aug 2026997,029$1.1M00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026910,006$1.0M-10,202−1.1%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026693,288$797K-423,848−37.9%
Hilton Capital Management, LLCunchanged · filed 4 Aug 2026548,950$631K00.0%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026508,220$584K+44,536+9.6%
CM Management, LLCadded · filed 13 Aug 2026450,000$518K+50,000+12.5%
31 Mar 2023 – 30 Jun 2026
315272Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Aaron G.L. Fletcher Company insiderDirector, 10% owner · last 17 Jun 20261 · 1
Bios Memory Spv I, Lp Company insiderDirector, 10% owner · last 17 Jun 20261 · 1
Brett P. Monia Company insiderDirector · last 17 Jun 20260 · 0
Ellen B. Richstone Company insiderDirector · last 17 Jun 20261 · 0
Jack A. Khattar Company insiderDirector · last 17 Jun 20260 · 0
Peggy Wallace Company insiderDirector · last 17 Jun 20262 · 0
John Brendan Doyle Company insiderChief Financial Officer · last 1 May 20261 · 0
Anthony Caggiano Company insiderChief Medical Officer · last 16 Apr 20261 · 0
Lisa Ricciardi Company insiderCEO & President · last 16 Apr 20265 · 0
Bios Advisors Gp, Llc Company insiderDirector, 10% owner · last 18 Jun 20250 · 0
Bios Fund Iii, Lp Company insiderDirector, 10% owner · last 18 Jun 20250 · 0
Bios Equity Partners Ii, Lp Company insiderDirector, 10% owner · last 7 Jun 20240 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-139%
Share count trendFY 2025 · to 20 Mar 20260.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$36.8M

Analyst forecasts

No analyst forecasts yet.